TrialDiabetes, obesity & metabolism2024

Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis.

Emily R Hankosky et al.PubMed ↗Publisher ↗

No numbers read from the abstract.